E
Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
E
Sell
11/21/2024Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 11/21/2024 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 15.9 to 13.15.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 11/21/2024 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 15.9 to 13.15.
D
Sell
3/25/2024Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index and total return index.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index and total return index.
E
Sell
3/7/2024Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 3/7/2024 due to a significant decline in the growth index, solvency index and volatility index. Total revenue declined 48% from $25 to $13, operating cash flow declined 7.83% from -$37.69M to -$40.64M, and the quick ratio declined from 16.41 to 15.82.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 3/7/2024 due to a significant decline in the growth index, solvency index and volatility index. Total revenue declined 48% from $25 to $13, operating cash flow declined 7.83% from -$37.69M to -$40.64M, and the quick ratio declined from 16.41 to 15.82.
D
Sell
2/20/2024Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 2/20/2024 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.2554 to -$0.2023, EBIT increased 10.42% from -$65.91M to -$59.04M, and operating cash flow increased 3.77% from -$39.16M to -$37.69M.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 2/20/2024 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.2554 to -$0.2023, EBIT increased 10.42% from -$65.91M to -$59.04M, and operating cash flow increased 3.77% from -$39.16M to -$37.69M.
E
Sell
9/11/2023Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 9/11/2023 due to a decline in the volatility index.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D- on 9/11/2023 due to a decline in the volatility index.
D
Sell
8/24/2023Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 8/24/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 15.26% from -$46.21M to -$39.16M, and earnings per share increased from -$0.2683 to -$0.2554.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D- from E+ on 8/24/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 15.26% from -$46.21M to -$39.16M, and earnings per share increased from -$0.2683 to -$0.2554.
E
Sell
3/14/2023Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 02/09/2023.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 99.99% from $35.74M to $3, earnings per share declined from -$0.15 to -$0.2829, and EBIT declined 78.3% from -$37.26M to -$66.44M.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 99.99% from $35.74M to $3, earnings per share declined from -$0.15 to -$0.2829, and EBIT declined 78.3% from -$37.26M to -$66.44M.
D
Sell
5/16/2022Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 05/16/2022.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Total revenue declined 80.4% from $2.82M to $553, EBIT declined 47.22% from -$46.52M to -$68.49M, and operating cash flow declined 44.25% from -$33.17M to -$47.85M.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Total revenue declined 80.4% from $2.82M to $553, EBIT declined 47.22% from -$46.52M to -$68.49M, and operating cash flow declined 44.25% from -$33.17M to -$47.85M.
D
Sell
5/4/2022Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Lyell Immunopharma, Inc. (LYEL) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the volatility index, efficiency index and total return index. Net income declined 71.27% from -$48.88M to -$83.71M, and total capital declined 5.32% from $1.05B to $997.61M.
Lyell Immunopharma, Inc. (LYEL) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the volatility index, efficiency index and total return index. Net income declined 71.27% from -$48.88M to -$83.71M, and total capital declined 5.32% from $1.05B to $997.61M.
D
Sell
9/10/2021None
Lyell Immunopharma, Inc. (LYEL) was downgraded to D from U on 09/10/2021.
Lyell Immunopharma, Inc. (LYEL) was downgraded to D from U on 09/10/2021.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
